½ÃÀ庸°í¼­
»óǰÄÚµå
1587428

±Þ¼º ³ú½Ç¿Ü¹è¾× ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¿ëµµº°, ȯÀÚ À¯Çüº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Acute External Ventricular Drain Market Size, Share & Trends Analysis Report By Application (Traumatic Brain Injury, Subarachnoid Hemorrhage, Intracerebral Hemorrhage), By Patient Type (Pediatric, Adult), By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 110 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

±Þ¼º ³ú½Ç¿Ü¹è¾× ½ÃÀå ¼ºÀå ¹× µ¿Çâ:

Grand View ResearchÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°è ±Þ¼º ³ú½Ç¿Ü¹è¾× ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 4¾ï 3,270¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ½ÃÀåÀº 2025³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 7.9%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âÁ¸ ¹æ½Ä¿¡ ºñÇØ Àç·¡½Ä ¹æ½ÄÀÇ Ã¤Åà Áõ°¡, ±Þ¼º ³ú¼öµÎÁõÀÇ À¯º´·ü Áõ°¡, ±Þ¼º±â ³ú½Ç¿Ü ¹è¾×¼ú¿¡ ´ëÇÑ ±â¼úÀûÀ¸·Î Áøº¸µÈ ÀåºñÀÇ Ã¤Åà Áõ°¡°¡ ¿¹Ãø ±â°£ µ¿¾È ¾÷°è ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

EVD´Â ±Þ¼º ¼öµÎÁõ Ä¡·á¿¡ ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. ¼öµÎÁõÀº ³úÀÇ Ãø³ú½Ç Áß Çϳª¿¡ EVD¸¦ ¼³Ä¡ÇÏ¿© °úµµÇÑ ¼ö¾×À» ¹èÃâÇØ¾ß ÇÏ´Â ÀÇ·á ÀÀ±Þ »óȲÀÔ´Ï´Ù. ¸Å³â LMIC¿¡¼­ 74¸¸ °Ç, HIC¿¡¼­ ¾à 3¸¸ °ÇÀÇ ³ú¼öµÎÁõÀ¸·Î ³ú¼ö¼úÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¸¶Âù°¡Áö·Î ¼öµÎÁõ Çùȸ¿¡ µû¸£¸é ¼öµÎÁõÀº ¾à 100¸¸ ¸íÀÇ ¹Ì±¹Àο¡°Ô ¿µÇâÀ» ¹ÌĨ´Ï´Ù.

ÀÌ ¼Ò½ÄÅë¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â ¿µ¾Æ 770¸í Áß 1¸íÀÌ ¼öµÎÁõÀ» ¾Î°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¿¬±¸¿¡ µû¸£¸é ³ú½Ç ³» ÃâÇ÷Àº ¿µ¾Æ ÈÄõ¼º ¼öµÎÁõÀÇ °¡Àå ºó¹øÇÑ ¿øÀÎÀ̸ç, EVD¸¦ ÅëÇÑ Á¶±â °³ÀÔ(»ýÈÄ 25 ÀÏ ÀÌÇÏ)ÀÌ ½Å°æ ÇÐÀû °á°ú¸¦ °³¼± ÇÒ ¼ö ÀÖ´Ù´Â ¿¬±¸ °á°ú°¡ ÀÖÀ¸¸ç, EVD´Â À§ÀÇ Áúº´¿¡ °¡Àå ¸¹ÀÌ »ç¿ëµÇ±â ¶§¹®¿¡ ÀÌ·¯ÇÑ ¿äÀÎÀº ¾÷°è¿¡ Á÷Á¢ÀûÀÎ ¿µÇâÀ» ¹ÌĨ´Ï´Ù.

¶ÇÇÑ, ³ú¼Õ»ó ÈÄ È¯ÀÚÀÇ È¸º¹À» µ½´Â °¡Àå È¿°úÀûÀÎ Ä¡·á ¹× Ä¡·á¹ýÀ» ã±â À§ÇØ º¸Á¶±Ý ¹èºÐ ¹× ½ÂÀÎ, ÅõÀÚ µî ´Ù¾çÇÑ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê°¡ °¢±¹¿¡¼­ ½ÃÇàµÇ°í ÀÖ½À´Ï´Ù. ¼öµÎÁõ Çùȸ¿¡ µû¸£¸é 2021³â¿¡ ¾à 1,200¸¸ ´Þ·¯°¡ ¿¬±¸¿¡ ÅõÀڵǾúÀ¸¸ç, ij³ª´ÙÀÇ ¼öµÎÁõ Áúȯ Ä¡·á ¿¬±¸ ¹× °³¹ß¿¡ 3,500¸¸ ´Þ·¯ÀÇ ¿¬¹æ ÀÚ±ÝÀÌ Ãß°¡·Î Áö¿øµÇ¾ú½À´Ï´Ù.

¶ÇÇÑ, 2022³â 4¿ù ¹Ì±¹ NIH´Â ¼öµÎÁõ À¯¾ÆÀÇ ³úô¼ö¾×À» Æò°¡ÇÏ´Â »õ·Î¿î ¹æ¹ýÀ» ¿¬±¸Çϱâ À§ÇØ ¿¬±¸Àڵ鿡°Ô 285¸¸ ´Þ·¯ÀÇ º¸Á¶±ÝÀ» Áö±ÞÇß½À´Ï´Ù. ¾Õ¼­ ¾ð±Þ ÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ ½ÃÀåÀº °¡±î¿î Àå·¡¿¡ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±Þ¼º ³ú½Ç¿Ü¹è¾× ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®:

  • ¿ëµµº°·Î´Â ¿Ü»ó¼º ³ú¼Õ»ó(TBI)ÀÌ 2024³â 33.9%·Î °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â Àü ¼¼°è ¼ö¼ú °Ç¼öÀÇ Áõ°¡¿Í ÇÔ²² TBIÀÇ À¯º´·üÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù.
  • ȯÀÚ À¯Çüº°·Î´Â ¼Ò¾Æ ȯÀÚ À¯ÇüÀÌ ½Å»ý¾Æ ¼öµÎÁõ Ä¡·á¸¦ À§ÇÑ ¼ö¼ú °Ç¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó 2024³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 8.1%ÀÇ °¡Àå ºü¸¥ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, Pediatric Neurosurgery¿¡ µû¸£¸é, ¹Ì±¹¿¡¼­´Â ¸Å³â ¾à 69,000¸íÀÇ ¼öµÎÁõ ȯÀÚ°¡ Åð¿øÇÏ´Â °ÍÀ¸·Î º¸°íµÇ°í ÀÖ½À´Ï´Ù.
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Þ¼º ³ú½Ç ¹è¾×±â ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È 8.26%ÀÇ °¡Àå ºü¸¥ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ¼±Áø±¹°ú ½ÅÈï±¹¿¡¼­ ÀÎÁöµµ°¡ ³ô¾ÆÁö°í ÁÖ¿ä ±â¾÷ÀÇ ÅõÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È »ó´çÇÑ ¼ºÀå·üÀÇ ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ±Þ¼º ³ú½Ç¿Ü¹è¾× ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ºñÁî´Ï½º ȯ°æ ºÐ¼®
    • ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTLE ºÐ¼®

Á¦4Àå ±Þ¼º ³ú½Ç¿Ü¹è¾× ½ÃÀå : ¿ëµµ ºñÁî´Ï½º ºÐ¼®

  • ¿ëµµ ½ÃÀå Á¡À¯À², 2024³â ¹× 2030³â
  • ¿ëµµ ºÎ¹® ´ë½Ãº¸µå
  • ¿ëµµº°, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®, 2018-2030³â
  • ¿Ü»ó¼º ³ú¼Õ»ó
  • ÁöÁÖ¸·ÇÏÃâÇ÷
  • ³ú³»ÃâÇ÷
  • ±âŸ ºñ¿Ü»ó¼º ¼öµÎÁõ

Á¦5Àå ±Þ¼º ³ú½Ç¿Ü¹è¾× ½ÃÀå : ȯÀÚ À¯Çü ÃßÁ¤¡¤µ¿Ç⠺м®

  • ȯÀÚ À¯Çüº° ½ÃÀå Á¡À¯À², 2024³â ¹× 2030³â
  • ȯÀÚ À¯Çü ºÎ¹® ´ë½Ãº¸µå
  • ȯÀÚ À¯Çüº° ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®, 2018³â¿¡¼­ 2030³â
  • ¼Ò¾Æ
  • ¼ºÀÎ

Á¦6Àå ±Þ¼º ³ú½Ç¿Ü¹è¾× ½ÃÀå : ¿ëµµ¿Í ȯÀÚ À¯Çüº° Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â ¹× 2030³â
  • Áö¿ª ½ÃÀå ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø µ¿Ç⠺м®, 2018³â¿¡¼­ 2030³â :
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ÄÝ·Òºñ¾Æ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹

Á¦7Àå °æÀï »óȲ

  • Âü¿©ÀÚ °³¿ä
  • ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Ç ºÐ¼®
  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ °³¿ä/¸®½ºÆ®
    • Medtronic
    • Integra LifeSciences
    • Natus
    • Fuji Systems
    • Spiegelberg GmbH &Co. KG
    • Sophysa
    • Neuromedex GmbH
ksm 24.11.20

Acute External Ventricular Drain Market Growth & Trends:

The global acute external ventricular drain market size is anticipated to reach USD 432.7 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.9% from 2025 to 2030. Rising adoption of conventional over the traditional method, increasing prevalence of acute hydrocephalus, and increasing adoption of technologically advanced devices for acute external ventricular drain are driving the industry's growth over the forecast period.

EVDs provide benefits for the treatment of acute hydrocephalus. Hydrocephalus is a medical emergency that requires the placement of an EVD into one of the brain's lateral ventricles to drain excess CSF. Each year, 740,000 instances of hydrocephalus in LMICs and about 30,000 in HICs require neurosurgery. Similarly, according to Hydrocephalus Association, hydrocephalus affects about 1 million Americans.

As per the same source, one in every 770 babies develops hydrocephalus in the U.S. Intraventricular hemorrhage is the most frequent cause of acquired hydrocephalus in babies, and studies have indicated that early intervention with an EVD (at the age of 25 days or younger) leads to improved neurological results. Since EVDs are most used in the abovementioned conditions, these factors have directly impacted the industry.

Furthermore, government initiatives such as grant allocation and approval, and investments to identify the most effective care and treatments to aid patient recovery after a brain injury are being implemented in various countries. According to the Hydrocephalus Association, approximately USD 12 million in research was invested in 2021, with an additional USD 35 million in federal funding provided for the study and development of hydrocephalus disease care in Canada.

Additionally, in April 2022, researchers were given a US 2.85 Mn NIH grant to explore a novel method for evaluating cerebrospinal fluid in infants with hydrocephalus. As a result of the aforementioned factors, the market is predicted to increase significantly in the near future.

Acute External Ventricular Drain Market Report Highlights:

  • By application, Traumatic Brain Injury (TBI) accounted for the largest revenue share of 33.9% in 2024. This is due to the increasing prevalence of TBI along with an increase in the number of surgeries globally
  • Based on patient type, the pediatric patient type segment is expected to grow at the fastest CAGR of 8.1% from 2024 to 2030,due to an increase in the number of surgical procedures to treat hydrocephalus in newborn babies. For instance, according to Pediatric Neurosurgery, approximately 69,000 hospital discharges of patients with hydrocephalus are reported each year in the U.S.
  • Asia Pacific acute external ventricular drain market is expected to witness the fastest CAGR of 8.26% over the forecast period. This can be attributed to the increasing awareness and rising investment of key players in the developed and emerging nations, which are some of the major factors responsible for the significant growth rate during the forecast period

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Patient Type
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Acute External Ventricular Drain Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Acute External Ventricular Drain Market: Application Business Analysis

  • 4.1. Application Market Share, 2024 & 2030
  • 4.2. Application Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 4.4. Traumatic Brain Injury
    • 4.4.1. Traumatic Brain Injury Market, 2018 - 2030 (USD Million)
  • 4.5. Subarachnoid Hemorrhage
    • 4.5.1. Subarachnoid Hemorrhage Market, 2018 - 2030 (USD Million)
  • 4.6. Intracerebral Hemorrhage
    • 4.6.1. Intracerebral Hemorrhage Market, 2018 - 2030 (USD Million)
  • 4.7. Other Non-traumatic Hydrocephalus Conditions
    • 4.7.1. Other Non-traumatic Hydrocephalus Conditions Market, 2018 - 2030 (USD Million)

Chapter 5. Acute External Ventricular Drain Market: Patient Type Estimates & Trend Analysis

  • 5.1. Patient Type Market Share, 2024 & 2030
  • 5.2. Patient Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Patient Type, 2018 to 2030 (USD Million)
  • 5.4. Pediatric
    • 5.4.1. Pediatric Market, 2018 - 2030 (USD Million)
  • 5.5. Adult
    • 5.5.1. Adult Market, 2018 - 2030 (USD Million)

Chapter 6. Acute External Ventricular Drain Market: Regional Estimates & Trend Analysis by Application and Patient Type

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key country dynamic
      • 6.4.2.2. Regulatory framework
      • 6.4.2.3. Competitive insights
      • 6.4.2.4. U.S. Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key country dynamic
      • 6.4.3.2. Regulatory framework
      • 6.4.3.3. Competitive insights
      • 6.4.3.4. Canada Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key country dynamic
      • 6.4.4.2. Regulatory framework
      • 6.4.4.3. Competitive insights
      • 6.4.4.4. Mexico Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key country dynamic
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive insights
      • 6.5.2.4. UK Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key country dynamic
      • 6.5.3.2. Regulatory framework
      • 6.5.3.3. Competitive insights
      • 6.5.3.4. Germany Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key country dynamic
      • 6.5.4.2. Regulatory framework
      • 6.5.4.3. Competitive insights
      • 6.5.4.4. France Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key country dynamic
      • 6.5.5.2. Regulatory framework
      • 6.5.5.3. Competitive insights
      • 6.5.5.4. Italy Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key country dynamic
      • 6.5.6.2. Regulatory framework
      • 6.5.6.3. Competitive insights
      • 6.5.6.4. Spain Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. China
      • 6.6.2.1. Key country dynamic
      • 6.6.2.2. Regulatory framework
      • 6.6.2.3. Competitive insights
      • 6.6.2.4. China Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Japan
      • 6.6.3.1. Key country dynamic
      • 6.6.3.2. Regulatory framework
      • 6.6.3.3. Competitive insights
      • 6.6.3.4. Japan Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key country dynamic
      • 6.6.4.2. Regulatory framework
      • 6.6.4.3. Competitive insights
      • 6.6.4.4. India Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key country dynamic
      • 6.6.5.2. Regulatory framework
      • 6.6.5.3. Competitive insights
      • 6.6.5.4. South Korea Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key country dynamic
      • 6.6.6.2. Regulatory framework
      • 6.6.6.3. Competitive insights
      • 6.6.6.4. Australia Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key country dynamic
      • 6.7.2.2. Regulatory framework
      • 6.7.2.3. Competitive insights
      • 6.7.2.4. Brazil Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key country dynamic
      • 6.7.3.2. Regulatory framework
      • 6.7.3.3. Competitive insights
      • 6.7.3.4. Argentina Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.4. Colombia
      • 6.7.4.1. Key country dynamic
      • 6.7.4.2. Regulatory framework
      • 6.7.4.3. Competitive insights
      • 6.7.4.4. Colombia Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.5. Argentina
      • 6.7.5.1. Key country dynamic
      • 6.7.5.2. Regulatory framework
      • 6.7.5.3. Competitive insights
      • 6.7.5.4. Argentina Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. Saudi Arabia
      • 6.8.2.1. Key country dynamic
      • 6.8.2.2. Regulatory framework
      • 6.8.2.3. Competitive insights
      • 6.8.2.4. Saudi Arabia Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. UAE
      • 6.8.3.1. Key country dynamic
      • 6.8.3.2. Regulatory framework
      • 6.8.3.3. Competitive insights
      • 6.8.3.4. UAE Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. South Africa
      • 6.8.4.1. Key country dynamic
      • 6.8.4.2. Regulatory framework
      • 6.8.4.3. Competitive insights
      • 6.8.4.4. South Africa Acute External Ventricular Drain Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Medtronic
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Integra LifeSciences
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Natus
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Fuji Systems
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Spiegelberg GmbH & Co. KG
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Sophysa
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Neuromedex GmbH
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦